# Skeletal Muscle Relaxants, Non-Benzodiazepine

This is a subcategory of Central Nervous System (CNS) Agents.

## Decision Trees

- [Skeletal Muscle Relaxants, Non-Benzodiazepine - Baclofen Solution, Fleqsuvy](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNkwwRERUVThSRTZNUkxYODEwMkEyMUpCTyQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}
- [Skeletal Muscle Relaxants, Non-Benzodiazepine - Carisoprodol](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMUcwOTdWSUQ2MTBJWk1MTFpMQ0pLTElLNCQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}
- [Skeletal Muscle Relaxants, Non-Benzodiazepine - Chlorzoxazone, Cyclobenzaprine, Cyclobenzaprine ER, Lyvispah, Metaxalone, Orphenadrine, Tizanidine Cap](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUOVRJNUZaMU9HQ1pCSUZWWURRQ0ZJQURLRCQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                               | Generic Name                                        | Quantity | Time (Days) |
| :-------------------------------------- | :-------------------------------------------------- | :------: | :---------: |
| Baclofen Tab                            |                                                     |          |             |
| Chlorzoxazone 250, 500 MG <sup>QL</sup> | Chlorzoxazone Tab 250 MG & 500 MG                   |   136    |     34      |
| Cyclobenzaprine 5, 10 MG <sup>QL</sup>  | Cyclobenzaprine HCI Tab (all strengths excl 7.5 MG) |   102    |     34      |
| Dantrolene                              |                                                     |          |             |
| Methocarbamol <sup>QL</sup>             | Methocarbamol Tab 500 MG                            |   272    |     34      |
| Methocarbamol <sup>QL</sup>             | Methocarbamol Tab 750 MG                            |   136    |     34      |
| Tizanidine Tab <sup>QL</sup>            | Tizanidine HCI Tab 2 MG                             |   272    |     34      |
| Tizanidine Tab <sup>QL</sup>            | Tizanidine HCI Tab 4 MG                             |   136    |     34      |

### Non-Preferred

| Non-Preferred                           | Generic Name                               |         Quantity          |        Time (Days)        |
| :-------------------------------------- | :----------------------------------------- | :-----------------------: | :-----------------------: |
| Baclofen Solution                       |                                            |                           |                           |
| Carisoprodol                            |                                            |                           |                           |
| Chlorzoxazone 375, 750 MG <sup>QL</sup> | Chlorzoxazone Tab 375 MG & 750 MG          | Determined pursuant to PA | Determined pursuant to PA |
| Cyclobenzaprine 7.5 MG <sup>QL</sup>    | Cyclobenzaprine HCI Tab 7.5 MG             | Determined pursuant to PA | Determined pursuant to PA |
| Cyclobenzaprine ER <sup>QL</sup>        | Cyclobenzaprine HCI ER Cap (all strengths) | Determined pursuant to PA | Determined pursuant to PA |
| Fleqsuvy                                |                                            |                           |                           |
| Lyvispah                                |                                            |                           |                           |
| Metaxalone                              |                                            |                           |                           |
| Orphenadrine                            |                                            |                           |                           |
| Tizanidine Cap                          |                                            |                           |                           |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least **30 days** with at least **one preferred** drug
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics, requests must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Baclofen Solution

Additional Baclofen Solution Criteria

-   Must provide documentation of trial with baclofen tablets or justification why a non-solid oral dosage form is indicated

### Carisoprodol (Soma)

Additional Carisoprodol (Soma) Criteria

-   Must provide medical justification that no other muscle relaxant or agent to treat fibromyalgia, or any musculoskeletal condition, would serve the clinical needs of the patient

### Subsequent Authorization

Subsequent Authorization Criteria

-   Must provide documentation of patientâ€™s clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=48){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=18){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
